Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2026)
Protagonist Therapeutics (PTGX) posted Current Deferred Revenue of $6.3 million for Q1 2026, down 34.22% sequentially from $9.5 million in Q4 2025, and down 62.82% YoY from $16.9 million in Q1 2025.
Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Current Deferred Revenue for 10 years, with the latest figure at $6.3 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 62.82% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (down 62.82% YoY) and the FY2025 annual result came in at $9.5 million, down 49.45% from the prior year.
- Current Deferred Revenue declined to $6.3 million in Q1 2026 per PTGX's latest filing, from $9.5 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $45.0 million in Q1 2024 and troughed at $3000.0 in Q3 2023.
- A 5-year average of $11.9 million and a median of $11.9 million in 2025 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue plunged 98.57% in 2022, then jumped 656433.33% in 2024.
- Over 5 years, Current Deferred Revenue stood at $69000.0 in 2022, then sank by 95.65% to $3000.0 in 2023, then surged by 629600.0% to $18.9 million in 2024, then tumbled by 49.45% to $9.5 million in 2025, then tumbled by 34.22% to $6.3 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.3 million, $9.5 million, and $14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.66 Mn |
| Mar 31, 2026 | 6.28 Mn |
| Dec 31, 2025 | 9.55 Mn |
| Sep 30, 2025 | 14.20 Mn |
| Jun 30, 2025 | 14.69 Mn |
| Mar 31, 2025 | 16.90 Mn |
| Dec 31, 2024 | 18.89 Mn |
| Sep 30, 2024 | 19.70 Mn |
| Jun 30, 2024 | 20.12 Mn |
| Mar 31, 2024 | 45.00 Mn |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Dec 31, 2022 | 69,000.00 |
| Sep 30, 2022 | 32,000.00 |
| Mar 31, 2022 | 768,000.00 |
| Dec 31, 2021 | 899,000.00 |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | 2.01 Mn |
| Mar 31, 2021 | 5.77 Mn |
| Dec 31, 2020 | 14.48 Mn |